Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics! of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining ;58 failed to achieve this threshold. An immunohistochemi- I cal study was performed using Ki-67 and GFAP antibodies. i Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second f (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temo-zolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.